Trials / Completed
CompletedNCT03889444
Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
Drug Utilization Study in Patients Receiving Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 141 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexamethasone intravitreal implant | Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice. |
Timeline
- Start date
- 2019-01-15
- Primary completion
- 2019-06-07
- Completion
- 2019-06-07
- First posted
- 2019-03-26
- Last updated
- 2020-06-22
- Results posted
- 2020-06-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03889444. Inclusion in this directory is not an endorsement.